EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Protective Role of Ginsenoside F1-Enriched Extract (SGB121) in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

Bo Yoon Chang, In Kim, Hyungmin Park, Sunchang Kim, Sung Yeon Kim

Nutrients · 2025

DOI: 10.3390/nu17233693 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2025. Verfasst von Bo Yoon Chang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Research and Development, College of Pharmacy, Wonkwang University, 460 Iksan-daero, Iksan-si 54538, Republic of Korea. Hauptthemen laut MEDLINE: Ginsenosides, Plant Extracts, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Objectives: Ginsenoside F1, a pharmacologically active saponin derived from Panax ginseng, exhibits diverse bioactivities, but its use is limited because it is difficult to purify and has high production costs. To overcome these challenges, a ginsenoside F1-enriched extract named SGB121 was developed. This study aimed to evaluate the therapeutic efficacy of SGB121 in a high-fat, high-carbohydrate (HFHC) diet-induced metabolic dysfunction-associated fatty liver disease (MAFLD) mouse model and to elucidate its mechanism of action using F1-based cellular assays.

Methods

Male C57BL/6 mice (6 weeks old) were fed an HFHC diet to induce MAFLD and were treated with SGB121. Hepatic lipid accumulation, oxidative stress markers, and metabolic parameters were analyzed. In parallel, human hepatocellular carcinoma (HepG2) cells exposed to free fatty acids (FFAs) were used to assess oxidative stress and lipid accumulation. Mechanistic studies were conducted using purified F1 to examine adenosine monophosphate-activated protein kinase (AMPK) activation and related pathways.

Results

SGB121 reduced hepatic lipid accumulation, malondialdehyde (MDA) levels, and fasting insulin while restoring glutathione (GSH) content and improving the homeostasis model assessment of insulin resistance (HOMA-IR) in MAFLD mice. In FFA-treated HepG2 cells, both SGB121 and F1 decreased reactive oxygen species (ROS), suppressed sterol regulatory element-binding protein 1 (SREBP1), enhanced peroxisome proliferator-activated receptor-α (PPARα) and β-oxidation, and restored insulin receptor substrate (IRS)/protein kinase B (Akt)/glucose transporter 2 (GLUT2) signaling.

Conclusions

SGB121 ameliorates MAFLD and related metabolic dysfunction through antioxidant, lipid-regulating, and insulin-sensitizing actions, highlighting its potential as a safe multifunctional nutraceutical for MAFLD management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GinsenosidesPlant ExtractsFatty LiverNon-alcoholic Fatty Liver DiseaseAnimalsMaleMice, Inbred C57BLHumansHep G2 CellsMiceOxidative StressDiet, High-FatLiverLipid MetabolismDisease Models, AnimalInsulin ResistanceAMP-Activated Protein KinasesSterol Regulatory Element Binding Protein 1Panax

Stichwörter der Autor:innen

antioxidant activityfunctional nutraceuticalginsenoside F1-enriched extract (SGB121)insulin sensitizationmetabolic dysfunction-associated fatty liver disease (MAFLD)

Substanzen

GinsenosidesPlant ExtractsAMP-Activated Protein KinasesSterol Regulatory Element Binding Protein 1

Autor:innen und Institutionen

  • Institute of Pharmaceutical Research and Development, College of Pharmacy, Wonkwang University, 460 Iksan-daero, Iksan-si 54538, Republic of Korea.
  • Cellonix Co. Ltd., 84, Gukgasikpum-ro, Wanggung-myeon, Iksan-si 54576, Republic of Korea.
  • Department of Biological Sciences, Korea Advanced Institute of Science and Technology, 291 Daehak-Ro, Yuseong-Gu, Daejeon 34141, Republic of Korea.
  • Intelligent Synthetic Biology Center, 291 Daehak-Ro, Yuseong-Gu, Daejeon 34141, Republic of Korea.

Zitieren

APA

Chang, B. Y., Kim, I., Park, H., Kim, S., & Kim, S. Y. (2025). Protective Role of Ginsenoside F1-Enriched Extract (SGB121) in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). Nutrients. https://doi.org/10.3390/nu17233693

Vancouver

Chang BY, Kim I, Park H, Kim S, Kim SY. Protective Role of Ginsenoside F1-Enriched Extract (SGB121) in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). Nutrients. 2025. doi:10.3390/nu17233693

BibTeX
@article{Chang2025,
  author = {Chang, Bo Yoon and Kim, In and Park, Hyungmin and Kim, Sunchang and Kim, Sung Yeon},
  title = {Protective Role of Ginsenoside F1-Enriched Extract (SGB121) in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)},
  journal = {Nutrients},
  year = {2025},
  doi = {10.3390/nu17233693}
}
Kostenlos starten →